Project Title Rescuing Fragile X Syndrome by Targeting p70 S6 Kinase 1 Abstract Fragile X syndrome (FXS) is caused by the lack of fragile X mental retardation protein, a negative regulator of translation. We previously showed that mTORC1 signaling, as measured by phosphorylated p70 S6 kinase 1 (S6K1) and elF4E-elF4G interactions, is elevated in FXS model mice. We then found that genetic ablation of S6K1 could correct molecular, synaptic/ and behavioral phenotypes displayed by the FXS mice. These findings have laid the groundwork for this proposal, where our central hypothesis is that excessive activation of S6K1 is a causative factor in the molecular, synaptic, and behavioral abnormalities in FXS. To test this hypothesis, we propose to 1) determine whether the S6K1 inhibitor PF-4708671 reverses phenotypes displayed by FXS model mice, 2) determine whether inhbition/deletion of S6K1 corrects exaggerated translation by reducing ribosome transit time in FXS model mice, and 3) determine whether excessive activation of S6K1 contributes to exaggerated translation and increased RTT in cells from FXS patients. These studies have the potential to identify new therapeutic targets for the treatment of FXS, and by extension, other developmental disabilities

Public Health Relevance

Fragile X syndrome (FXS) is the most commonly inherited cause of intellectual disability and autism. In this proposal we describe experiments designed to determine whether S6K1 can be a therapeutic target to reverse exaggerated protein synthesis, synaptic dysfunction, and aberrant behaviors displayed by FXS model mice.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1-DSR-Y (53))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Massachusetts Medical School Worcester
United States
Zip Code
Huynh, T N; Santini, E; Mojica, E et al. (2018) Activation of a novel p70 S6 kinase 1-dependent intracellular cascade in the basolateral nucleus of the amygdala is required for the acquisition of extinction memory. Mol Psychiatry 23:1394-1401
Liu, Botao; Li, Yue; Stackpole, Emily E et al. (2018) Regulatory discrimination of mRNAs by FMRP controls mouse adult neural stem cell differentiation. Proc Natl Acad Sci U S A 115:E11397-E11405
Santini, Emanuela; Huynh, Thu N; Longo, Francesco et al. (2017) Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice. Sci Signal 10:
Gao, Fen-Biao; Richter, Joel D; Cleveland, Don W (2017) Rethinking Unconventional Translation in Neurodegeneration. Cell 171:994-1000
Bhattacharya, Aditi; Mamcarz, Maggie; Mullins, Caitlin et al. (2016) Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice. Neuropsychopharmacology 41:1991-2000
Richter, Joel D; Bassell, Gary J; Klann, Eric (2015) Dysregulation and restoration of translational homeostasis in fragile X syndrome. Nat Rev Neurosci 16:595-605
Huynh, Thu N; Shah, Manan; Koo, So Yeon et al. (2015) eIF4E/Fmr1 double mutant mice display cognitive impairment in addition to ASD-like behaviors. Neurobiol Dis 83:67-74
Gross, Christina; Hoffmann, Anne; Bassell, Gary J et al. (2015) Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back. Neurotherapeutics 12:584-608
Richter, Joel D; Coller, Jeff (2015) Pausing on Polyribosomes: Make Way for Elongation in Translational Control. Cell 163:292-300